The companies Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026 across private and public funding types. In this article, we break down last month’s private and public fundraising activity, looking at the largest rounds in more detail.
Table of contents
Private biotech funding rounds in June 2026
First, let’s take a look at the private biotech investments in June 2026, breaking them down by value, location, funding type, and therapeutic subsector.
Biggest private biotech funding rounds by value
Last month, NewLimit was the company to raise the most money, bringing in $435 million in series C funding. This will help it to bring its first aging reprogramming medicine into human clinical trials next year. According to the company, this accelerated timeline to trial has been driven by the breakthrough discovery of a prototype medicine that reverses cell age in old human liver cells.
Meanwhile, in second place in the private biotech fundraising standings last month, Ollin Biosciences raised $330 million in series B funding to support global phase 3 trials of OLN324, a next-generation VEGF/Ang2 bispecific antibody for the treatment of diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), as well as the advancement of another drug candidate into clinical development this year.
Beren Therapeutics followed closely behind in the rankings, after securing a $300 million financing to support the potential commercial launch of adrabetadex, as well as the development of a long-term patient access and family support program designed to reduce the burden for those living with infantile-onset Niemann-Pick disease, type C throughout their treatment journey. The financing comprised a $135 million equity financing alongside up to $165 million in a strategic financing facility with Hercules Capital across a senior secured debt and royalty structure.
Private biotech funding rounds by location
June 2026 saw North American companies back on top again after Europe’s somewhat surprising domination of the fundraising rankings in May. With 19 rounds in total, North America attracted $2.696 billion in private biotech funding last month, while European companies only brought home $266.4 million from four rounds. Meanwhile, the Asia-Pacific region had a very disappointing month, with no significant funding rounds.
Private biotech funding rounds by funding type
We can see from the table below that series B funding attracted the most rounds and the most money last month, with nine rounds and $1.109 billion raised. Series A funding, meanwhile, wasn’t too far behind, with $822.8 million raised from seven rounds.
Private biotech funding rounds by therapeutic subsector
Although the therapeutic subsector of immunological diseases attracted the most rounds last month, with four in total, it was genetic disorders that attracted the most money, bringing in a total of $655 million from three rounds. Ophthalmology players also followed closely behind, achieving a total of $613 million from three rounds.
Public biotech funding rounds in June 2026
Now, let’s check out the public biotech fundraising rounds that occurred in June 2026, breaking them down by value and therapeutic subsector.
Public biotech funding by value
June 2026 saw Parabilis Medicines set a new record with the largest ever new stock sale for a venture-backed biotech company, as it raised an incredible $670 million from an initial public offering (IPO). The company is focused on creating medicines for undruggable targets and is progressing a novel therapeutic modality called Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.
In joint second place, Enliven Therapeutics and Kardigan both raised $400 million last month; Enliven, focused on the development of small molecule therapies, raised its money from a public offering, and Kardigan, a cardiovascular-focused company, brought in its money from an IPO.
Meanwhile, in third place, Mineralys Therapeutics priced a $150 million public offering. The company is focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea, and other diseases driven by dysregulated aldosterone.
Public biotech funding by therapeutic subsector
Oncology players dominated the public biotech fundraising rankings last month, attracting four rounds and raising $1.132 billion in funding. Meanwhile, cardiovascular disease companies came second on the list, raising a total of $550 million from two rounds.
Month-to-month comparison of biotech fundraising
Below is a graph showing a month-to-month comparison of private and public biotech fundraising, looking at the total amount of money raised per month in 2026.
Private companies had another impressive month in June, bringing in a total of $2.963 billion – the third-highest total of the year for private biotech fundraising. Public fundraising also achieved its third-highest total of the year, as companies brought in $1.761 billion; this came despite there only being eight significant funding rounds last month, and was in large part thanks to Parabilis’ record raise, extending a streak of large biotech IPOs so far this year that has seen 12 startups securing more than $4.1 billion combined.
